<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04909697</url>
  </required_header>
  <id_info>
    <org_study_id>SichuanPPHospital</org_study_id>
    <nct_id>NCT04909697</nct_id>
  </id_info>
  <brief_title>Treatment of ARDS With Sivelestat Sodium</brief_title>
  <acronym>TOAWSS</acronym>
  <official_title>Efficacy of Sivelestat Sodium in the Treatment of ARDS With SIRS, a Multicenter Double-blind Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sichuan Provincial People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neutrophil elastase (NE) released by neutrophils play an important role in inflammatory&#xD;
      cascade and lung tissue injury of ARDS.Inhibition of NE is expected to prevent the&#xD;
      pathophysiological process of ARDS and alleviate lung injury. Siverestat sodium is a specific&#xD;
      inhibitor of NE, which has been proved by basic and observational clinical studies to be&#xD;
      effective in alleviating lung injury of ARDS, but there is a lack of prospective multi-center&#xD;
      randomized controlled clinical trials.Therefore, this study was intended to evaluate the&#xD;
      efficacy of sivelestat sodium in the treatment of ARDS patients with SIRS in a multicenter&#xD;
      randomized controlled clinical trial&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">July 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>oxygenation improvement rate</measure>
    <time_frame>day 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>ventilator free days</measure>
    <time_frame>day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Invasive mechanical ventilation rate</measure>
    <time_frame>day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of stay in ICU</measure>
    <time_frame>day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of stay in hospital</measure>
    <time_frame>day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28 days mortality</measure>
    <time_frame>day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU mortality</measure>
    <time_frame>day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acquired infections</measure>
    <time_frame>day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>oxygenation improvement rate</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>oxygenation improvement rate</measure>
    <time_frame>day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of severe adverse effect</measure>
    <time_frame>day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>activity of neutrophil elastase in plasma</measure>
    <time_frame>day0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>activity of neutrophil elastase in plasma</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>activity of neutrophil elastase in plasma</measure>
    <time_frame>day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>activity of neutrophil elastase in plasma</measure>
    <time_frame>day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>concentration of IL-6</measure>
    <time_frame>day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>concentration of IL-6</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>concentration of IL-6</measure>
    <time_frame>day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>concentration of IL-6</measure>
    <time_frame>day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>concentration of IL-10</measure>
    <time_frame>day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>concentration of IL-10</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>concentration of IL-10</measure>
    <time_frame>day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>concentration of IL-10</measure>
    <time_frame>day 5</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">324</enrollment>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sivelestat Sodium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sivelestat sodium</intervention_name>
    <description>4.8mg/kg sivelestat sodium was given in 50ml normal saline, and was continuously pumped in the dark for 24h, equivalent to 0.2mg/kg/h.Applied for 5 consecutive days</description>
    <arm_group_label>Sivelestat Sodium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>50ml normal saline was continuously pumped in the dark for 24h. Applied for 5 consecutive days</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females &gt; 18 years old and &lt;75 years old (non-pregnant, non-lactating&#xD;
             females).&#xD;
&#xD;
          2. Patients fulfilled the Berlin diagnostic criteria of acute respiratory distress&#xD;
             syndrome, with a arterial oxygen partial pressure (PaO2) to fraction of inspired&#xD;
             oxygen (FiO2) between 150 mmHg and 300 mmHg.&#xD;
&#xD;
          3. Signed written informed consent has been obtained&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of chronic respiratory disease&#xD;
&#xD;
          2. Single cardiogenic pulmonary edema&#xD;
&#xD;
          3. Apach2 score â‰¥21 points&#xD;
&#xD;
          4. Complicated with end-stage disease, or poor prognosis judged by the clinical doctor in&#xD;
             charge&#xD;
&#xD;
          5. ARDS course&gt;3 days&#xD;
&#xD;
          6. Agranulocytosis or receiving immunosuppressive agents or high doses of corticosteroids&#xD;
             (methylprednisolone&gt;40mg/day)&#xD;
&#xD;
          7. Pregnancy or breastfeeding&#xD;
&#xD;
          8. Participated in this study&#xD;
&#xD;
          9. Do not agree to participate in this experiment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaobo Huang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sichuan Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hongli He, Ph.D.</last_name>
    <phone>+86-28-87393633</phone>
    <email>hhl0408@163.com</email>
  </overall_contact>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 20, 2021</study_first_submitted>
  <study_first_submitted_qc>May 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2021</study_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sichuan Provincial People's Hospital</investigator_affiliation>
    <investigator_full_name>He Hongli</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Acute Respiratory Distress Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sivelestat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

